4.7 Review

Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis

出版社

AMER THORACIC SOC
DOI: 10.1164/rccm.201006-0894CI

关键词

idiopathic pulmonary fibrosis; survival; prognosis; predictors; clinical course

资金

  1. CV Therapeutics
  2. Genzyme
  3. Gilead Science
  4. Nektar
  5. Actelion
  6. Amira
  7. Bayer
  8. Fibrogen
  9. NIH
  10. ASP/Chest Foundation
  11. Boehringer Ingelheim
  12. InterMune
  13. ImmuneWorks

向作者/读者索取更多资源

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some patients live much longer. Respiratory failure resulting from disease progression is the most frequent cause of death. To date we have limited information as to predictors of mortality in patients with IPF, and research in this area has failed to yield prediction models that can be reliably used in clinical practice to predict individual risk of mortality. The goal of this concise clinical review is to examine and summarize the current data on the clinical course, individual predictors of survival, and proposed clinical prediction models in IPF. Finally, we will discuss challenges and future directions related to predicting survival in IPF.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据